摘要
目的探讨糖尿病肾病患者在进行血液透析的同时配合重组人促红素与蔗糖铁治疗的效果。方法选取2022年3月—2024年3月厦门市第三医院收治的90例糖尿病肾病患者为研究对象,根据不同的治疗方式分为对照组(予以重组人促红素,45例)、观察组(予以重组人促红素与蔗糖铁,45例),比较两组血糖指标、贫血指标、铁代谢指标、肾功能指标、治疗总有效率。结果治疗后,观察组空腹血糖、餐后2 h血糖、糖化血红蛋白、糖化白蛋白水平均低于对照组,差异均有统计学意义(P均<0.05)。治疗后,观察组血红蛋白水平、平均红细胞血红蛋白浓度、红细胞计数、血细胞比容均高于对照组,差异均有统计学意义(P均<0.05)。治疗后,观察组血清肌酐、血清尿素氮、血尿酸、尿白蛋白排泄率均低于对照组,差异均有统计学意义(P均<0.05)。治疗后,观察组铁调素低于对照组,铁蛋白、转铁蛋白、转铁蛋白饱和度均高于对照组,差异均有统计学意义(P均<0.05)。观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。结论糖尿病肾病血液透析患者接受蔗糖铁联合重组人促红素治疗,不仅能够保持血糖稳定,促进肾功能恢复,还能改善贫血状态,提高治疗效果。
Objective To investigate the effect of recombinant human erythropoietin and iron sucrose in the treatment of diabetic nephropathy patients with hemodialysis.Methods A total of 90 diabetic nephropathy patients admitted to Xiamen Third Hospital from March 2022 to March 2024 were selected as the study objects.According to different treatment methods,they were divided into control group(given recombinant human erythropoitin,45 cases)and observation group(given recombinant human erythropoitin and iron sucrose,45 cases).Blood glucose indexes,anemia indexes,iron metabolism indexes,renal function indexes and total effective rate of treatment were compared between the two groups.Results After treatment,the levels of fasting blood glucose,2-hour postprandial blood glucose,glycated hemoglobin A1c and glycated albumin in observation group were lower than those in control group,and the differences were statistically significant(all P<0.05).After treatment,the hemoglobin level,mean erythrocyte hemoglobin concentration,erythrocyte count and hematocrit in observation group were higher than those in control group,and the differences were statistically significant(all P<0.05).After treatment,the serum creatinine,serum urea nitrogen,blood uric acid and urinary albumin excretion rate in observation group were lower than those in control group,and the differences were statistically significant(all P<0.05).After treatment,ferrimodulin in observation group was lower than that in control group,and ferritin,transferrin and transferrin saturation were higher than those in control group,and the differences were statistically significant(all P<0.05).The total effective rate of treatment in the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).Conclusion The treatment of diabetic nephropathy hemodialysis patients with sucrose iron combined with recombinant human erythropoietin can not only maintain stable blood glucose,promote the recovery of renal function,but also improve anemia and improve the therapeutic effect.
作者
许清华
庄福春
XU Qinghua;ZHUANG Fuchun(Department of Nephrology and Immunology,Xiamen Third Hospital,Xiamen 361100,Fujian,China)
出处
《糖尿病新世界》
2024年第20期10-13,共4页
Diabetes New World
关键词
糖尿病肾病
血液透析
蔗糖铁
重组人促红素
贫血状态
Diabetic nephropathy
Hemodialysis
Iron sucrose
Recombinant human erythropoietin
Anemic state
